LEMS: Enhancing Diagnostic Accuracy and Access to Therapy to Improve Muscle Function

Released On
March 25, 2021

Expires On
April 1, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Neurology, Pediatrics, Primary Care

Topic(s)
Lambert-Eaton myasthenic syndrome

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine (PIM) and PlatformQ Health Education, LLC.

Working in collaboration with the National Organization for Rare Disorders (NORD).

This activity is supported by educational grants from Acadia Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc., Biogen, Catalyst Pharmaceuticals, and Mitsubishi Tanabe Pharma America, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for neurologists; primary care, internal medicine, and pediatric clinicians; psychiatrists; nurse practitioners; physician assistants; physical therapists; physiatrists; social workers; genetics counsellors; pharmacists; and other HCPs who recognize, diagnose and treat patients with neurologic diseases.

Estimated Time to Complete

This activity consists of 5 sessions which should take approximately 5 hours to complete.

Learning Objectives

At the conclusion of this activity, participants will be able to:

LEMS: Enhancing Diagnostic Accuracy and Access to Therapy to Improve Muscle Function

  • Describe the clinical symptoms of LEMS, the correlation with small cell lung cancer, and the importance of early recognition and testing to confirm a diagnosis
  • Explain how new channel blocker formulations may fill a therapeutic gap for people with LEMS
  • Adopt a multidisciplinary approach to LEMS management, engaging HCPs from multiple disciplines, including oncologists and neuro-muscular specialists

Pathophysiology and Targeted Treatments: Enhancing Outcomes in MG

  • Describe the correlation between an enhanced understanding of the pathophysiology of myasthenia gravis and emerging confirmatory diagnostic serologic tests
  • Describe the efficacy, safety, and place in therapy of current and emerging treatments for myasthenia gravis
  • Explain the importance of multidisciplinary care with neuromuscular specialists, hematologists, thoracic surgeons, pulmonologists, oncologists, physical and occupational therapists, primary and specialist care physicians

ALS: The Era of Disease Modifying Therapies

  • Identify patient characteristics and symptoms that suggest a diagnosis of ALS so appropriate testing can be performed to rule out mimicking conditions and confirm a diagnosis
  • Explain the therapeutic rationale of current and emerging treatments for the management of ALS
  • Describe the importance of coordinated specialized multidisciplinary ALS care and its impact on quality of life and extend survival

SMA: Early Detection to Enhance Access to Genetic Testing and Disease Modifying Therapies

  • Describe the link between genetic mutations, the onset of symptoms, and the importance of early recognition and diagnosis of SMA to prevent irreversible loss of nerve function and ensure early access to effective and potentially curative treatment
  • Differentiate current and emerging treatment options to produce functional SMN protein levels
  • Explain the importance of a multidisciplinary team approach, including gastroenterology, nutritionist, pulmonology, orthopedics, and physical-therapy members, to maximize quality of life in patients with SMA

Rett Syndrome: Early Recognition and Emerging agents to Reduce Disease Burden

  • Recognize the subtle signs and symptoms of Rett syndrome to confirm diagnosis early in the disease course
  • Appraise the therapeutic potential of agents currently being investigated for the treatment of patients with Rett syndrome
  • Describe the need for coordinated comprehensive care provided at a specialty clinic, including neurology, developmental pediatrics, gastroenterology, orthopedics, speech, and occupational- and physical-therapy specialists

Faculty

Ericka P. Greene, MD

Associate Professor of Neurology
Vice Chair of Education
Stanley H. Appel Department of Neurology
Weill Cornell Medical College-Houston
Methodist Hospital

Amanda C. Peltier, MD, MS

Associate Professor of Neurology and Medicine
Vanderbilt University Medical Center

Terry D. Heiman-Patterson, MD

Professor of Neurology
Director, Neurodegenerative Disease Center
Director, MDA ALS Center of Hope
Temple University Lewis Katz School of Medicine

Julie A. Parsons, MD

Haberfeld Family Endowed Chair in Pediatric
Neuromuscular Disorders
Professor of Clinical Pediatrics and Neurology
University of Colorado School of Medicine
Children's Hospital Colorado

David N. Lieberman, MD, PhD

Attending Child Neurologist
Assistant, Department of Neurology
Instructor of Neurology, Harvard Medical School
Boston Children’s Hospital
Department of Neurology

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Live Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Date of Release/Expiration

Live Activity
Thursday, March 25, 2021:

  • 1:00pm – 2:00pm ET: LEMS: Enhancing Diagnostic Accuracy and Access to Therapy to Improve Muscle Function
  • 2:00pm – 3:00pm ET: Pathophysiology and Targeted Treatments: Enhancing Outcomes in MG
  • 3:00pm – 4:00pm ET: ALS: The Era of Disease Modifying Therapies

Thursday, April 1, 2021:

  • 2:00pm – 3:00pm ET: SMA: Early Detection to Enhance Access to Genetic Testing and Disease Modifying Therapies
  • 3:00pm – 4:00pm ET: Rett Syndrome: Early Recognition and Emerging agents to Reduce Disease Burden

Enduring Material
The enduring material will be available from March 25, 2021 to April 1, 2022

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Ericka P. Greene, MD

  • Royalty: Speaker Bureau – Alexion, CLS Behring
  • Consulting Fees: Argenx Inc.

Amanda C. Peltier, MD, MS

  • Consulting Fees: Akcea, Alnylam, CLS Behring

Terry D. Heiman-Patterson, MD

  • Consulting Fees: Biogen, Biohaven, Cytokinetics Evolution Medical Communication, Evidera, ITF Pharma, IQVIA, MTPA, Orphazyme, Samus
  • Other: HMA Hospitals, MJH Holdings, Sate of California Institute for Regenerative Med, WebMD

Julie A. Parsons, MD

  • Consulting Fees: Biogen, Scholar Rock, Genentech Roche, Novartis
  • Contracted Research: Biogen, Scholar Rock, AveXis

David N. Lieberman, MD, PhD

  • Consulting Fees: Taysha Gene Therapies
  • Contracted Research: Site PI for clinical trials supported by Acadia Pharmaceuticals, GW Research Limited, Anavex Life Sciences Corporation, and the Rett Syndrome Research Trust

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Planner

Carole Drexel, Medical Director, PlatformQ Health Education, LLC; has no financial relationships to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unapproved/Off Label Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in this activity. To participate in the activity, go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com

Technical Support:
For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.

PlatformQ Health Privacy Policy:

By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.

Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.

In plain English, here is what we affirm:

  • You can change your registration profile at any time from our “Profile” page
  • To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
  • You can end your association with PlatformQ Health at any time
  • PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
  • EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting support@PlatformQHealth.com with the subject line “Data Request”

You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: www.platformqhealth.com/privacy-policy/